US Stock MarketDetailed Quotes
PALI Palisade Bio
- 3.8900
- +0.3200+8.96%
Close Oct 18 16:00 ET
- 3.8500
- -0.0400-1.03%
Post 20:02 ET
4.61MMarket Cap-209P/E (TTM)
4.2199High3.5700Low136.52KVolume3.5700Open3.5700Pre Close542.65KTurnover11.74%Turnover RatioLossP/E (Static)1.18MShares22.350052wk High0.46P/B4.52MFloat Cap3.140052wk Low--Dividend TTM1.16MShs Float594000.0000Historical High--Div YieldTTM18.20%Amplitude3.1400Historical Low3.9740Avg Price1Lot Size
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
% Chg
No Data
Palisade Bio Stock Forum
Palisade Bio Provides Update on Progress Toward Launch of Phase 1 Human Clinical Study for Lead Program, PALI-2108 for the Treatment of Ulcerative Colitis
Palisade Bio (Nasdaq: PALI) has made significant progress towards launching its Phase 1 human clinical study for PALI-2108, a locally activated PDE4 inhibitor prodrug for treating ulcerative colitis (UC). The company has:
1. Completed nonclinical safety and toxicity studies
2. Finalized Phase 1 clinical trial desi...
Palisade Bio Reports Data Demonstrating PDE4B Expression in Patient Cohorts Could be Utilized as a Potential Marker for Patient Stratification
Palisade Bio (Nasdaq: PALI) has reported promising data on PDE4B expression as a potential marker for patient stratification in Ulcerative Colitis (UC)treatment.
The company's analysis, conducted in collaboration with Strand Life Sciences, revealed that 70% of adult colitis patients and 90% of pediatric colitis patients show P...
Palisade Bio, Inc. (Nasdaq: PALI) ("Palisade" or the "Company"), a biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases, has recently made a advancement in its drug development progr...
Palisade Bio, Inc.Thu, 11 July 2024 at 8:00 am GMT-4
Palisade Bio Announces Successful Completion of First GMP Manufacturing of PALI-2108 Drug Substance and Engineering Batches of Drug Product
Palisade Bio announced the successful completion of the first GMP manufacturing batch of its drug substance PALI-2108, targeted for treating moderate-to-severe ulcerative colitis (UC).
The company partnered with Eurofins for process development and scale-up. The drug substance has been utilized in completed murine and non-murine G...
No comment yet